에어로졸 전달 기기 시장 보고서 : 제품, 용도, 유통 채널 및 지역별(2024-2032년)

The global aerosol delivery devices market size reached US$ 47.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 73.4 Billion by 2032, exhibiting a growth rate (CAGR) of 4.9% during 2024-2032.

Aerosol delivery devices are used in drug delivery and treating respiratory disorders, such as asthma, obstructive lung diseases, cystic fibrosis, pulmonary arterial hypertension, infectious pulmonary. They lower dosage requirements, reduce systemic adverse effects and improve the ability of patients to self-administer medication. Some of the commonly available aerosol delivery devices are pressurized metered-dose inhalers, nebulizers, and valved holder chambers. At present, smart aerosol drug delivery devices are used in non-respiratory conditions, such as diabetes, analgesia, thyroid disorders, and genetic diseases, due to the advent of novel macromolecular medications.

Aerosol Delivery Devices Market Trends:

The global outbreak of the coronavirus disease (COVID-19) that leads to acute respiratory infections among patients represents one of the key factors driving the need for aerosol delivery devices. These devices assist in treating obstructive airway diseases at home and in healthcare settings. Apart from this, the rising prevalence of chronic respiratory infections due to surging air pollution levels, allergens and occupational risks, and the increasing number of individuals who smoke tobacco and drink is propelling the market growth. Moreover, a considerable rise in the geriatric population, which is more vulnerable to developing serious health illnesses, is positively influencing the demand for portable inhalation devices that are convenient and economical. Besides this, market players are developing novel aerosol delivery devices that help treat chronic inflammation and infection in the lungs and improve airway clearance in patients with cystic fibrosis (CF). Furthermore, they are offering mini ultrasonic nebulizers and inhalers through e-commerce channels that have automatic memory and are easy to use while traveling. This, in confluence with the escalating demand for personalized drug therapy and the increasing use of online channels for purchasing medical supplies, is driving the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global aerosol delivery devices market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, application and distribution channel.

Breakup by Product:

Dry Powder Inhalers

Single Dose Inhalers

Multi Dose Inhalers

Metered Dose Inhalers

Conventional Pressurized Inhalers

Soft Mist Inhalers

Nebulizers

Jet Nebulizers

Ultrasonic Wave Nebulizers

Vibrating Mesh Nebulizers

Breakup by Application:

Asthma

Chronic Obstructive Pulmonary Disease (COPD)

Cystic Fibrosis

Non-Respiratory Diseases

Diabetes

Analgesia

Parkinson's Disease

Breakup by Distribution Channel:

Retail Pharmacies

Hospital Pharmacies

Online Stores

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Aerogen, GlaxoSmithKline plc, Johnson & Johnson, Koninklijke Philips N.V., Merck & Co. Inc., Metall Zug AG, Recipharm AB (publ), Teva Pharmaceutical Industries Ltd. and Vectura Group plc.

Key Questions Answered in This Report

• 1. What was the size of the global aerosol delivery devices market in 2023?
• 2. What is the expected growth rate of the global aerosol delivery devices market during 2024-2032?
• 3. What are the key factors driving the global aerosol delivery devices market?
• 4. What has been the impact of COVID-19 on the global aerosol delivery devices market?
• 5. What is the breakup of the global aerosol delivery devices market based on the product?
• 6. What is the breakup of the global aerosol delivery devices market based on the distribution channel?
• 7. What are the key regions in the global aerosol delivery devices market?
• 8. Who are the key players/companies in the global aerosol delivery devices market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Aerosol Delivery Devices Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Dry Powder Inhalers
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Single Dose Inhalers
    • 6.1.2.2 Multi Dose Inhalers
  • 6.1.3 Market Forecast
• 6.2 Metered Dose Inhalers
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Conventional Pressurized Inhalers
    • 6.2.2.2 Soft Mist Inhalers
  • 6.2.3 Market Forecast
• 6.3 Nebulizers
  • 6.3.1 Market Trends
  • 6.3.2 Key Segments
    • 6.3.2.1 Jet Nebulizers
    • 6.3.2.2 Ultrasonic Wave Nebulizers
    • 6.3.2.3 Vibrating Mesh Nebulizers
  • 6.3.3 Market Forecast

7 Market Breakup by Application

• 7.1 Asthma
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Chronic Obstructive Pulmonary Disease (COPD)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Cystic Fibrosis
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Non-Respiratory Diseases
  • 7.4.1 Market Trends
  • 7.4.2 Key Segments
    • 7.4.2.1 Diabetes
    • 7.4.2.2 Analgesia
    • 7.4.2.3 Parkinson's Disease
  • 7.4.3 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Retail Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Hospital Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Online Stores
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 3M Company
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Aerogen
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 GlaxoSmithKline plc
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Johnson & Johnson
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Koninklijke Philips N.V.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Merck & Co. Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Metall Zug AG
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
  • 14.3.8 Recipharm AB (publ)
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Teva Pharmaceutical Industries Ltd.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Vectura Group plc
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis